Compare Western Alliance Bancorporation (WAL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Western Alliance Bancorporation vs State Street SPDR S&P Biotech ETF — how do they compare? Western Alliance Bancorporation trades at $79.8 (market cap $8.84B), while State Street SPDR S&P Biotech ETF trades at $154.43. The key difference: Western Alliance Bancorporation pays a 2.07% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Western Alliance Bancorporation nearer its low. Which is the better fit depends on your goals.
| WAL | XBI | |
|---|---|---|
Market Cap | $8.84B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $96.08 | $164.28 |
52-Week Low | $66.70 | $85.16 |
Dividend Yield | 2.07% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
